Anorexia is a common manifestation of chronic diseases, including cancer. Here we investigate the contribution to cancer anorexia made by calcitonin gene-related peptide (CGRP) neurons in the parabrachial nucleus (PBN) that transmit anorexic signals. We show that CGRP PBN neurons are activated in mice implanted with Lewis lung carcinoma cells. Inactivation of CGRP PBN neurons before tumor implantation prevents anorexia and loss of lean mass, and their inhibition after symptom onset reverses anorexia. CGRP PBN neurons are also activated in Apc min/+ mice, which develop intestinal cancer and lose weight despite the absence of reduced food intake. Inactivation of CGRP PBN neurons in Apc min/+ mice permits hyperphagia that counteracts weight loss, revealing a role for these neurons in a 'nonanorexic' cancer model. We also demonstrate that inactivation of CGRP PBN neurons prevents lethargy, anxiety and malaise associated with cancer. These findings establish CGRP PBN neurons as key mediators of cancer-induced appetite suppression and associated behavioral changes.
a r t I C l e S Illness is associated with behavioral changes ('sickness behaviors'), which may be adaptive in the acute setting 1 but have deleterious consequences if they persist in patients with chronic disease. Notably, anorexia is common in patients with cancer-induced weight loss and, even when overt anorexia is absent, the ability to eat enough to compensate for and counter ongoing weight loss is often lacking. Although available evidence suggests that cancer anorexia arises from signals emanating from the tumor and/or associated inflammatory processes that impinge on neural circuits controlling feeding behavior 2 , a discrete population of neurons responsible for cancer anorexia has yet to be identified. The absence of this fundamental information may help to explain the ineffectiveness of current treatment options.
In the current work, we focused on the hypothesis that neurons in the external lateral parabrachial nucleus (PBN) that express calcitonin gene-related peptide (CGRP) mediate cancer anorexia, based on both their ability to potently suppress appetite when activated 3 and on evidence that they are situated downstream of neural systems activated by various cancer-related signals. Specifically, CGRP PBN neurons are activated by visceral signals that suppress feeding and are inhibited by hunger-promoting hypothalamic agouti-related peptide (AgRP) neurons 4, 5 , neurocircuits that are also implicated in cancer anorexia [6] [7] [8] . Moreover, CGRP PBN neurons are activated by spinally transmitted noxious stimuli and transduce affective-motivational aspects of pain 9 .
To test this hypothesis, we employed Cre-dependent viruses in transgenic mice to selectively manipulate CGRP PBN neurons in two established murine cancer models: implantable Lewis lung carcinoma (LLC) cells, which induce weight loss and anorexia, and Apc min/+ mice, which develop intestinal cancer due to an autosomal dominant mutation of the Apc gene 10 . Although Apc min/+ mice do not exhibit anorexia, they fail to increase their food intake in the face of weight loss 11, 12 , implying a disruption of the normal adaptive response to negative energy balance. Results of these studies demonstrate that activation of CGRP PBN neurons is required for the effect of cancer to both induce anorexia and malaise (LLC tumor model) and to prevent adaptive increases of food intake that mitigates weight loss (Apc min/+ mice).
RESULTS

CGRP PBN neurons are activated in LLC tumor-bearing mice
To determine whether CGRP PBN neurons are active during cancer anorexia, we implanted LLC tumor cells in Calca Cre:GFP/+ transgenic mice, which express GFP fused to Cre recombinase driven by the CGRP-encoding gene Calca (Fig. 1a) . Compared to sham-treated controls (including mice pair-fed to the intake of anorexic mice), tumor-bearing mice exhibited increased Fos expression in the external lateral PBN ( Fig. 1b and Supplementary Fig. 1 ). Approximately 80% of Fos-immunoreactive neurons in tumor-bearing mice corresponded to GFP-labeled CGRP PBN neurons, while 41% of CGRP PBN neurons expressed Fos (Fig. 1c,d) , a level comparable to what is observed in healthy mice following a large meal 4 . As sham-treated mice exhibited Fos in just 3% of CGRP PBN neurons, these data establish that CGRP PBN neurons were inappropriately active in tumorbearing mice.
Inactivation of CGRP PBN neurons prevents LLC-induced anorexia
To determine whether activation of CGRP PBN neurons is required for cancer anorexia, we injected an adeno-associated virus (AAV) expressing Cre-dependent tetanus toxin (TetTox) light chain (AAV1-DIO-GFP:TetTox) bilaterally into the PBN of Calca Cre:GFP/+ mice before LLC tumor implantation ( Fig. 2a) . Expression of TetTox prevents neurotransmitter release from Cre-expressing neurons 13 and therefore selectively and permanently inactivates CGRP PBN neurons. Bilateral TetTox inactivation of CGRP PBN neurons fully prevented a r t I C l e S anorexia in LLC tumor-bearing mice compared to tumor-bearing controls that received PBN injections of AAV1-DIO-GFP control virus ( Fig. 2b) . Indeed, tumor-bearing mice with bilateral CGRP PBN neuronal inactivation increased their food intake compared to baseline (before tumor implantation) and compared to sham-treated mice ( Fig. 2c) . Although LLC tumor-bearing mice with bilateral TetTox inactivation of CGRP PBN neurons tended to lose less weight than LLC tumor-bearing controls, the effect was not substantial ( Supplementary  Fig. 2a ). Notably, TetTox mice fed ad libitum also developed larger tumors than tumor-bearing controls (Supplementary Fig. 2b) .
CGRP PBN neurons have excitatory axonal projections to the central nucleus of the amygdala (CeA) and oval subnucleus of the bed nucleus of the stria terminalis (ovBNST; Fig. 2d,e) 3, 9 , brain areas involved in affective-motivational responses to stressful stimuli 14, 15 . Cancer anorexia was associated with increased Fos expression in both brain areas, and this effect was also prevented in TetTox mice ( Fig. 2f-h ) regardless of whether TetTox mice were fed ad libitum or were pair-fed to the intake of tumor-bearing controls (indicating that the outcome cannot be explained by differences of food intake). In addition to demonstrating that activation of CGRP PBN neurons is required for anorexia in the LLC tumor model, these data support the possibility that projections of these neurons to the CeA and ovBNST contributed to associated behavioral phenotypes.
Inhibiting CGRP PBN neurons reverses established LLCinduced anorexia
To investigate whether acute inhibition of CGRP PBN neurons is sufficient to ameliorate established cancer anorexia, we bilaterally transduced these neurons with either AAV1-DIO-hM 4 Di:mCherry or AAV1-DIO-mCherry control virus ( Fig. 3a) . With this approach, CGRP PBN neuronal activity remains intact until administration of clozapine-N-oxide (CNO), an otherwise inert drug that activates the inhibitory hM 4 Di receptor. To ensure uniform timing of CNO administration relative to anorexia onset, drug administration commenced after two consecutive days of food intake decline. Consistent with our findings in TetTox mice, CNO administration fully reversed anorexia in the hM 4 Di tumor-bearing group, whereas food intake continued to decline in the CNO-treated mCherry tumor group (Fig. 3b,c and Supplementary Fig. 3a,b) .
Although none of the CNO-treated hM 4 Di tumor-bearing mice met criteria for euthanasia (Online Methods), they were killed for analysis together with tumor-bearing controls such that study duration and days receiving CNO treatment did not differ between groups (Supplementary Fig. 3c,d) . CNO-induced CGRP PBN neuron inhibition prevented both tumor-induced weight loss ( Supplementary  Fig. 3e ,f) and activation of CGRP PBN neurons (percent of CGRP PBN neurons co-expressing Fos ± s.e.m.; 85.2 ± 4.1% mCherry LLC versus 2.2 ± 1.4% hM 4 Di LLC) and downstream CeA and ovBNST neurons ( Fig. 3d-g) . Acute inhibition of CGRP PBN neurons was therefore sufficient to ameliorate cancer anorexia after it was established.
Role of CGRP PBN neurons in LLC tumor-induced changes of energy expenditure and body composition
Cancer-induced weight loss is often associated with wasting of lean mass (cachexia), which can also contribute to cancer-related mortality 16 . To determine the role played by activation of CGRP PBN neurons in cancer-induced wasting of lean mass and associated increase of energy expenditure 17 , we measured body composition by quantitative magnetic resonance and energy expenditure (by indirect calorimetry) in TetTox mice and GFP controls before and after LLC tumor implantation ( Fig. 4a) . Although both groups exhibited comparable increases energy expenditure ( Fig. 4b-g ) and reductions of body fat mass compared to baseline ( Fig. 4h,k) , lean body mass was increased in TetTox mice ( Fig. 4l ) relative to GFP controls ( Fig. 4i ) in the first body composition measurement (LLC 1). This finding implicates CGRP PBN neuron activation in LLC-induced loss of lean mass, an effect that is independent of changes in either energy expenditure or fat mass.
A second body-composition analysis (LLC 2) was also performed after the onset of anorexia in GFP control mice ( Fig. 4j,m) at timepoints that varied according to the time when anorexia became evident in each animal ( Supplementary Fig. 4a,b ). Even after taking differences of tumor mass into account (LLC 2 minus tumor), TetTox mice did not exhibit the cancer-induced loss of lean body mass ( Fig. 4l and Supplementary Fig. 4f ) that was evident in GFP controls ( Fig. 4i and Supplementary Fig. 4e ). Moreover, whereas loss of fat mass increased between the first and second body-composition measurements in GFP mice ( Fig. 4h and Supplementary Fig. 4c ), TetTox mice were protected from further fat loss ( Fig. 4k and Supplementary Fig. 4d ). a r t I C l e S TetTox mice developed larger tumors than GFP control mice ( Supplementary Fig. 4g ). After the final body-composition scan, mice were killed for analysis and Fos staining was again undertaken to confirm efficacy of TetTox-induced CGRP PBN neuron inactivation. As expected, tumor-induced Fos immunoreactivity in the CeA and ovBNST was abolished in TetTox mice ( Supplementary Fig. 5a-d) . These results collectively indicate that inactivation of CGRP PBN neurons attenuates the loss of both lean and fat mass associated with cancer anorexia.
Involvement of CGRP PBN neurons in 'nonanorexic' Apc min+ mice
A cardinal feature of cancer anorexia is that, unlike in healthy animals and humans, progressive weight loss fails to trigger adaptive increases of food intake. Given the association between cancer and increased energy expenditure 18 , weight loss in the absence of increased feeding could reflect activation of anorexic neural circuitry that blocks the compensatory increase of feeding normally triggered by energy deficit. To address this issue and to extend our study of CGRP PBN neurons to a genetic cancer model, we used Apc min/+ mice, which begin to develop intestinal tumors as early as 4 weeks of age and start to lose body weight around 12 weeks of age 12, 19 despite maintaining food intake at baseline levels 11 .
Calca Cre:GFP/+ ::Apc min/+ control mice displayed increased Fos expression in CGRP PBN neurons compared to Calca Cre:GFP/+ littermates at 16 weeks of age ( Fig. 5a-c and Supplementary Fig. 6 ). To examine a r t I C l e S the effect of inactivating CGRP PBN neurons on feeding behavior, we bilaterally transduced these neurons with AAV1-DIO-GFP:TetTox at 10 weeks of age, before the onset of weight loss. In both male and female Calca Cre:GFP/+ ::Apc min/+ mice, food intake was increased and weight loss prevented by inactivation of CGRP PBN neurons compared to either of two control groups (Calca Cre:GFP/+ ::Apc min/+ and Calca Cre:GFP/+ littermates injected with GFP virus; Fig. 5d-g and Supplementary Fig. 7d,e ).
The male cohort was killed for analysis at 17 weeks of age for Fos analysis, regardless of body weight differences between groups (some GFP Apc min/+ control mice were euthanized earlier because they met euthanasia criteria). Apc min/+ mice had increased Fos expression (compared to cancer-free littermates) in the CeA and ovBNST, which was abolished with TetTox inactivation of CGRP PBN neurons (Supplementary Fig. 7a-c) . The female cohort study continued until mice were euthanized based on the euthanasia criterion of losing 20% or more of peak body weight. Whereas the control group of tumor-bearing females continuously lost weight until criteria for euthanasia were met (average age ± s.e.m., 18.67 ± 0.53 weeks), the body weights of TetTox Apc min/+ mice remained comparable to cancer-free littermates throughout most of their lives ( Supplementary  Fig. 7e ). Weeks later (average age ± s.e.m., 22.30 ± 0.52 weeks), the latter animals exhibited a rapid drop in food intake ( Supplementary  Fig. 7f,g) and, after being killed for analysis, were found to have signs of gastrointestinal obstruction (stomachs distended with food despite cessation of feeding). Notably, these mice never exhibited signs of distress, which was assessed on a daily basis before they were killed (data not shown), suggesting a role for CGRP PBN neurons in this outcome as well. Thus, whereas CGRP PBN neuronal inactivation prolonged life by restoring the ability of Apc min/+ mice to mount an adaptive hyperphagia that prevents weight loss, it did not protect animals from the underlying malignancy.
Role of CGRP PBN neurons in cancer-induced malaise
In humans, loss of appetite resulting from cancer or illness is typically associated with malaise, characterized by feelings of discomfort, anxiety and lack of motivation. To investigate the role played by CGRP PBN neuronal activation in these responses, we measured sickness behaviors in mice with either intact or TetToxinactivated CGRP PBN neurons before and after LLC tumor implantation. To control for differences of food intake between groups, TetTox mice were pair-fed to the intake of tumor-bearing control mice until completion of behavioral studies, at which point the pair-feeding regimen was terminated and ad libitum access to food was restored ( Supplementary Fig. 8a) .
Lethargy can be assessed in rodents by measuring locomotor activity 20 . Compared to tumor-bearing controls, locomotor activity was increased in TetTox tumor-bearing mice, whether measured as the total distance moved or the average velocity of movement ( Fig. 6a-d) .
To determine whether CGRP PBN neuronal activation was similarly required for cancer-induced anxiety, we used open-field and elevatedplus-maze tests. Anxiety-like behavior was increased in tumor-bearing controls, and this manifestation of cancer was prevented by inactivation of CGRP PBN neurons ( Fig. 6e,f,h,i) . Tumor-bearing control mice also spent more time in a hunched posture (a sign of malaise), and this effect was prevented by CGRP PBN neuron inactivation (Fig. 6g,j) . Nesting behavior offers an additional measure of malaise and lack of motivation in rodents 21, 22 . Using a protocol that takes into account a r t I C l e S the rate and quality of nest construction, no differences were detected between GFP and TetTox mice at baseline. Whereas tumor implantation had no effect on nest construction in TetTox mice, control mice failed to finish their nest within 24 h (Fig. 6k,l) .
After completion of behavioral studies, tumor-bearing TetTox mice were allowed ad libitum access to food. Unlike tumor-bearing controls, which by that point had become moribund and anorexic, TetTox mice nearly doubled their food intake upon termination of the pair-feeding regimen (Fig. 6m) . This hyperphagic response reversed cancer-induced weight loss (Supplementary Fig. 8b) , which suggests that the ability to eat enough additional food to compensate for weight loss was undermined by cancer anorexia and that this ability was restored by CGRP PBN neuronal inactivation. These outcomes cannot be attributed to differences in tumor mass, since tumors tended to be larger in TetTox mice than in controls, although the difference did not reach statistical significance (P = 0.09) in this experiment (Supplementary Fig. 8c ).
DISCUSSION
Insight into neural circuits mediating cancer anorexia is essential for a better understanding of the underlying disease process and for the development of effective treatments. Here using viral and genetic techniques to visualize and selectively manipulate CGRP PBN neurons, we established that these neurons were activated in tumor-bearing mice and that this activation was required for cancer-induced appetite suppression and malaise.
Because of its key role in energy homeostasis, the hypothalamic arcuate nucleus has been a prominent focus of prior work in this field. In healthy animals, weight loss activates AgRP neurons 23 , which stimulates appetite 24 , reduces metabolic rate 25 and inhibits neural circuits that suppress appetite, including circuits involving both POMC-expressing neurons 26 and CGRP PBN neurons 4 . One hypothesis invoked to explain cancer anorexia proposes that, despite weight loss and appropriate changes in circulating hormones 27, 28 , inflammationmediated activation of POMC neurons increases downstream melanocortin signaling via the melanocortin-4 receptor (MC4R) and thereby inhibits food intake despite ongoing weight loss 29, 30 . The same mechanism is proposed to simultaneously block activation of AgRP neurons 8 , which functionally oppose POMC neurons in part by releasing AgRP, an endogenous MC4R antagonist 31 . Indeed, cancer anorexia can be attenuated by central administration of MC4R antagonists 32, 33 . Since CGRP PBN neurons express MC4R 34 and are supplied with inhibitory projections from AgRP neurons 4 , they are potential mediators of cancer anorexia lying downstream of the arcuate nucleus.
However, cancer anorexia is not always ameliorated by central injection of MC4R antagonists 35 , and cancer anorexia can be associated with seemingly appropriate responses of arcuate nucleus neurons to weight loss 8, 27, [36] [37] [38] . Furthermore, neurocircuits additional to the arcuate hypothalamus are implicated in other models of inflammatory anorexia 39 . For example, anorexia following administration of lipopolysaccharide, an endotoxin that induces systemic inflammation and anorexia, cannot be reversed by activation of AgRP neurons 40 but is ameliorated by inhibiting CGRP PBN neurons 3 . Mechanisms underlying cancer anorexia may therefore vary depending on the type of cancer and/or severity of cancer-induced inflammation, and they likely involve extra-hypothalamic anorexigenic circuits.
These considerations support a model in which cancer-associated inflammatory cytokines induce anorexia in part by activating the .74, P = 0.0013; treatment, F 1,13 = 1.032, P = 0.3283; distance moved, two-way repeated-measures ANOVA; interaction, F 1,13 = 1.59, P = 0.2299; time, F 1,13 = 1.02, P = 0.3310; treatment, F 1,13 = 0.28, P = 0.6045; time in hunched posture, two-way repeated-measures ANOVA; interaction, F 1,13 = 9.82, P = 0.0079; time, F 1,13 = 5.92, P = 0.0302; treatment, F 1,13 = 16.26, P = 0.0014). (k,l) Quantification and representative images (24-h timepoint) of nesting behavior before (pre) and 16 d after tumor implantation (two-way ANOVA; interaction, F 15, 156 = 3.01, P = 0.0003; time, F 5, 156 = 228.40, P < 0.0001; treatment, F 3, 156 = 44.61, P < 0.001). (m) Daily food intake of GFP and TetTox mice after tumor implantation (two-tailed Student's t test on day 17, t 13 = 6.36, P < 0.0001). TetTox mice were pair-fed to the intake of GFP mice until day 16, after which TetTox mice were allowed ad libitum access to food. Line graphs show mean ± s.e.m. Box plots show mean (+), median, quartiles (boxes) and range (whiskers) for each treatment. *P < 0.05, **P < 0.01, ***P < 0.001. See also Supplementary Figure 8 . a r t I C l e S unreported and potentially clinically relevant finding. CGRP PBN neuron inactivation also enabled animals to increase food intake to counteract cancer-induced weight loss. In Apc min/+ mice, this effect prevented cancer-induced weight loss, and in LLC tumor-bearing mice, it enabled robust hyperphagia after being pair-fed to the intake of LLC tumor-bearing controls.
That CGRP PBN neuron inactivation conferred the capacity of tumorbearing mice to increase food intake in response to weight loss implies that the brains of tumor-bearing mice did in fact receive appropriate energy-deficit signals but that activation of CGRP PBN neurons blocked their transduction into an adaptive feeding response. Our data suggest that the CeA and BNST lie downstream of CGRP PBN neurons in this anorexigenic pathway. Although CGRP PBN neurons do not have direct axonal projections to the arcuate nucleus, the CeA and BNST have extensive hypothalamic connections that may ultimately be integrated with hypothalamic homeostatic signals that regulate appetite 41 .
We selected the LLC and Apc min/+ cancer models for our studies because they differ in several key aspects, including their effect on feeding behavior (anorexia versus failure to escalate food intake to compensate), time-course of weight loss (weeks versus months), source of tumor (implantable versus genetic mutation) and tumor location (subcutaneous versus gastrointestinal). Given these differences, we suspect that CGRP PBN neurons represent a common node for suppression of appetite by many cancers, and additional studies are warranted to test this hypothesis. We also note that since activation of CGRP PBN neurons can prevent the expected compensatory increase in food intake during weight loss, this mechanism may contribute to weight loss even when food intake is not obviously affected.
Cancer anorexia, cachexia and tumor growth
Loss of lean body mass is a major contributor to cancer-related mortalities 16 that can potentially arise from circulating factors (released by either the tumor or the animal) acting on muscle tissue, combined with increased energy expenditure, metabolic dysregulation and reduced food intake 16 . Using the LLC tumor model, we provided evidence implicating activation of CGRP PBN neurons in this wasting process, since cancer-induced loss of lean body mass was ameliorated by inactivation of these neurons and prevention of anorexia. From this observation, one might predict that provision of sufficient calories would prevent or reverse weight loss in cancer patients. In the clinic, however, this is not typically observed, presumably because of an ongoing catabolic state that is not remedied by providing nutritional support 42 . This observation has diverted attention from the problem of anorexia because it implies that restoring normal food intake will not suffice to prevent cachexia, a problem compounded by the fact that conventional therapeutic agents used to stimulate appetite in cancer patients have glucocorticoid-like effects 43 that may exacerbate muscle wasting 44, 45 . In this context, our finding that inhibition of CGRP PBN neurons protected against loss of lean body mass raises the possibility that these neurons influence processes involved in cachexia independently of their effect on food intake. Future studies to examine the role of these neurons in cancer cachexia are therefore warranted.
Although our studies were not designed to investigate the roles of either CGRP PBN neurons or anorexia on tumor growth, we observed larger tumors in two separate experiments in which mice with inactive CGRP PBN neurons had ad libitum access to food. That this increase in tumor growth depends on increased food intake is consistent with evidence that mice fed the same amount of food as tumor-bearing control mice did not develop larger tumors. It remains possible, however, that activation of CGRP PBN neurons also elicited food intake-independent responses that limit tumor growth. Recent studies suggest that activation of CGRP PBN neurons contributes to chemotherapy-induced anorexia and weight loss 46 . Examination of tumor growth in mice receiving chemotherapy treatment will be needed to examine the potential clinical utility of inhibiting CGRP PBN neurons in cancer patients.
Cancer-induced malaise
Cancer patients often experience profound deterioration in quality of life as their disease progresses, marked by feelings of malaise and associated 'sickness behaviors' . Although these behavioral consequences of cancer likely have a complex, multifactorial etiology, the fact that tumor-bearing mice exhibit similar responses indicates that at least some of the underlying mechanisms are shared across species. We found that mice with implantable LLC tumors exhibited behavioral phenotypes suggestive of lethargy, anxiety and malaise. The observation that these behaviors were ameliorated by inactivation of CGRP PBN neurons suggests that in addition to suppressing appetite, cancer-induced activation of CGRP PBN neurons contributed to the associated affective-motivational state. These findings are consistent with an emerging view that the external lateral PBN (including CGRP neurons) plays a critical role in coordinating behavioral, affective and neuroendocrine responses to noxious stimuli 47 .
Future dissection of downstream CGRP PBN neuronal pathways may assist in determining whether anorexia and associated sickness behaviors involve separate or overlapping neural pathways. Because our behavioral studies were performed using a pair-feeding regimen, to prevent potentially confounding differences of intake between groups, the possibility can be considered that increased hunger (induced by pair-feeding) contributed to the effect of CGRP PBN neuron inactivation to alleviate sickness behaviors. We view this explanation as unlikely, however, since chronic food restriction in healthy mice does not increase homecage locomotor activity 48 and because anorexia and decreased locomotor activity are separable features of illness 20, 33 . Although anxiety-like behaviors are sensitive to perceived energy deficits 49, 50 , we note that even in sated mice, experimental activation of CGRP PBN neurons is sufficient to elicit behavioral stress responses 9 .
CONCLUSIONS
In summary, our data indicate that activation of CGRP PBN neurons is both necessary and sufficient to explain major affective-motivational features of cancer, including anorexia, lethargy, anxiety and malaise. Translation of these findings to the clinic may ultimately assist in the identification of therapeutics with the potential to substantially improve the quality of life of patients with cancer.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper. treatment began) and killed for analysis at the same time as mCherry tumor-bearing counterparts to account for differences in days receiving CNO treatment. All mice received their final CNO injection (2 mg/kg i.p.) 2 h before euthanasia and extraction of brain tissue for Fos analysis.
LLC cohort 4 (Fig. 4) . Mice received bilateral PBN injections of either AV1-DIO-GFP or AAV1-DIO-GFP:TetTox. Three weeks after virus injection and before tumor implantation, mice underwent a QMR scan to measure body composition, and then were singly housed in indirect calorimetry chambers for 4 d. For baseline calorimetry measurements, we analyzed data from the dark cycle on days 2-4 (after acclimation to chambers). After the baseline calorimetry measurements, mice were implanted with tumor cells and placed in their homecages, and then housed in calorimetry chambers for 4 d starting 13 d after tumor implantation. For post-tumor calorimetry, we analyzed dark-cycle data from 14-16 d after tumor implantation. On day 17 after tumor implantation, we examined body composition with QMR (this measurement occurred before development of anorexia). After development of anorexia (which occurred 2-7 d after the first post-tumor body composition measurement), mice underwent a final bodycomposition scan before being killed for analysis. We extracted the tumors and subtracted the tumor weight from the final lean body mass measurement.
Apc min/+ cohorts (Fig. 5) . For PBN Fos analysis, the first group of Calca Cre: GFP/+ ::Apc min/+ mice (male and female) were killed for analysis at 16 weeks of age. For feeding behavior analysis, Calca Cre:GFP/+ ::Apc min/+ mice received bilateral PBN injections of either AAV1-DIO-GFP or AAV1-DIO-GFP:TetTox at 10 weeks of age, and food intake and body weights were monitored starting at 12 weeks of age. Calca Cre:GFP/+ littermates were used as controls and received bilateral PBN injections of AAV1-DIO-GFP. The male cohort of animals were killed for analysis at 17 weeks of age (regardless of body weight); some were euthanized earlier if they met the pre-established criteria for euthanasia (loss of 20% peak body weight or cumulative distress score of 8; Supplementary table 1) . Brains from the male cohort were processed for immunohistochemical analysis of Fos in the CeA and ovBNST. The female cohort of mice was euthanized based on the pre-established criteria for euthanasia (loss of 20% peak body weight or cumulative distress score of 8; Supplementary table 1) .
LLC cohort 5 (Fig. 6) . For sickness-behavioral analyses of tumor-bearing mice with intact or inactivated CGRP PBN neurons, we used a within-subjects experimental design involving GFP and TetTox mice before and after tumor implantation. TetTox mice were pair-fed during days 5-16 after tumor implantation to control for differences in food intake. We conducted anxiety tests 4 d before and 15 d after tumor implantation. Nesting behavior was analyzed 3 d before and 16 d after tumor implantation. Locomotor activity was analyzed from data collected 5 d before and 13 d after tumor implantation.
Immunohistochemistry. For all immunohistochemical experiments, mice were anesthetized (Beuthanasia, 320 mg/kg delivered i.p.) and intracardially perfused with 0.1 M PBS followed by 4% paraformaldehyde. Brains were then extracted, postfixed in 4% paraformaldehyde overnight and cryoprotected in 0.1 M PBS containing 20% sucrose until the brains sunk in the sucrose solution. Coronal cryostat sections 30-µm thick were collected, and every third section of the PBN and BNST, or every fourth section of the CeA, were processed for immunolabeling and quantification. For co-labeling of GFP and Fos, sections were incubated for 16 h at room temperature (20-22 °C) in chicken anti-GFP (1:10,000, catalog # ab13970, lot #GR236651-4, Abcam) and goat anti-Fos (1:700, catalog # sc-52-G, lot #F1615, Santa Cruz Biotechnology). Because we ran out of our original Fos antibody, tissue in Figure 4 was stained with goat anti-Fos from a different lot (1:700, catalog # sc-52-G, lot #F1616 Santa Cruz Biotechnology). The sections were then washed and incubated for 2 h at room temperature in Alexa Fluor 488-conjugated donkey anti-chicken (1:400, Jackson ImmunoResearch) and CY5-conjugated donkey anti-goat (1:400, Jackson ImmunoResearch). microscopy and Fos analysis. Images were acquired at 10× and 20× magnification for figure presentation and quantification, respectively, using a laserscanning confocal microscope (FV1200, Olympus). Fos and GFP colocalization counts were performed using the Cell Counter feature on ImageJ (v. 1.48). Cell counts were obtained from two sections for each brain region corresponding to the following coordinates 58 : −5.15 mm and −5.25 mm from bregma, PBN (unilateral, left PBN); −1.55 mm and −1.75 mm from bregma, CeA (bilateral); 0.15 mm and 0.25 mm from bregma, BNST (bilateral).
Statistics.
Data were analyzed using Prism 5.0 (GraphPad Software). Sample sizes were estimated based on prior experience 4 and expected variability in behaviors between tumor-bearing animals. We excluded an animal from data analysis if post hoc histological analysis showed no viral transduction, as indicated by an absence of GFP or mCherry fluorescence. For graphs comparing two experimental conditions, we used unpaired two-tailed Student's tests. For graphs comparing multiple treatments (single timepoints), we used one-way repeated-measures ANOVA with Tukey's post hoc multiple comparisons tests. Datasets with multiple treatments and timepoints were analyzed with two-way repeated-measures ANOVA (time-repeated factor) followed by Bonferroni's post hoc tests. For analysis of Apc min/+ experiments, which involved euthanasia of mice during the study, we used regular (not repeated-measures) two-way ANOVA (time-repeated factor). Normality and variance were examined with Shapiro-Wilk tests and Bartlett's tests, respectively. A Supplementary methods checklist is available.
data availability. The data that support the findings of this study are available from the corresponding author upon reasonable request.
